Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments.

Therapeutics

Health Care

Biotechnology

AreteiaTx

Jorge Bartolome

Tom Denwood

Richard Fires, MBA, GPHR

Peter Wijngaard

Mark Kreston

Lex Kay

Kevin Wesbecker CPIM, CSCP

Herbert Vail

Christopher Courts, CPA

Calman Prussin, M.D.

Leadership Team

Clinical Operations Team

Teams at AreteiaTx

Leadership Team

Clinical Operations Team